Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade C 75.42 2.92% 2.14
BPMC closed up 2.92 percent on Wednesday, January 17, 2018, on 64 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
4 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical BPMC trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 50 DMA Bullish 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Fell Below 50 DMA Bearish 2.92%
Jan 16 180 Bearish Setup Bearish Swing Setup 2.92%
Jan 16 Expansion Pivot Sell Setup Bearish Swing Setup 2.92%
Jan 16 Wide Bands Range Expansion 2.92%
Jan 16 Oversold Stochastic Weakness 2.92%
Jan 12 Wide Bands Range Expansion -4.82%
Jan 11 NR7 Range Contraction -3.86%
Jan 11 Wide Bands Range Expansion -3.86%

Older signals for BPMC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 92.0
52 Week Low 31.38
Average Volume 510,793
200-Day Moving Average 56.6551
50-Day Moving Average 73.5354
20-Day Moving Average 76.9045
10-Day Moving Average 77.65
Average True Range 4.4393
ADX 14.97
+DI 21.48
-DI 21.65
Chandelier Exit (Long, 3 ATRs ) 71.1221
Chandelier Exit (Short, 3 ATRs ) 84.1479
Upper Bollinger Band 82.1038
Lower Bollinger Band 71.7052
Percent B (%b) 0.36
BandWidth 13.521445
MACD Line 0.7438
MACD Signal Line 1.3436
MACD Histogram -0.5998
Fundamentals Value
Market Cap 2.95 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -24.17
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 79.80
Resistance 3 (R3) 79.32 77.39 79.07
Resistance 2 (R2) 77.39 76.27 77.63 78.83
Resistance 1 (R1) 76.40 75.58 76.90 76.88 78.58
Pivot Point 74.47 74.47 74.71 74.71 74.47
Support 1 (S1) 73.48 73.35 73.98 73.96 72.26
Support 2 (S2) 71.55 72.66 71.79 72.01
Support 3 (S3) 70.56 71.55 71.77
Support 4 (S4) 71.04